{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-037051","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.564067+00:00","generated_at":"2026-05-31T09:19:43.372171+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"VYNE Therapeutics Q2 2024 net loss $9.4M; cash $78.1M funds milestones into 2025","bullets":["Net loss of $9.4M ($0.22 EPS) vs $10.1M ($3.09 EPS) in Q2 2023.","Cash, cash equivalents, restricted cash and marketable securities of $78.1M as of June 30, 2024.","Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo; top-line results expected mid-2025.","Phase 1a SAD/MAD trial of VYN202 ongoing; SAD data in Q3 2024, MAD data in Q4 2024.","Appointed Dr. Subhashis Banerjee as SVP of Clinical Development; previously at Bristol Myers Squibb."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-037051","json":"https://secwatch.observer/filing/0001628280-24-037051.json","markdown":"https://secwatch.observer/filing/0001628280-24-037051.md","text":"https://secwatch.observer/filing/0001628280-24-037051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000162828024037051/0001628280-24-037051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000162828024037051/mnlo-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:19:43.372171+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}